Novel Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease
The purpose of this reprint based on the Special issue "Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease", IJMS journal, MDPI, is to present the impact in clinical practice as well as in medical research of novel molecules that have been introduced in the treatment of...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_100830 | ||
| 005 | 20230623 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20230623s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-7684-8 | ||
| 020 | |a 9783036576855 | ||
| 020 | |a 9783036576848 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-7684-8 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a GP |2 bicssc | |
| 072 | 7 | |a PS |2 bicssc | |
| 100 | 1 | |a Vesa, Cosmin Mihai |4 edt | |
| 700 | 1 | |a Bungau, Simona Gabriela |4 edt | |
| 700 | 1 | |a Vesa, Cosmin Mihai |4 oth | |
| 700 | 1 | |a Bungau, Simona Gabriela |4 oth | |
| 245 | 1 | 0 | |a Novel Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
| 300 | |a 1 electronic resource (152 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a The purpose of this reprint based on the Special issue "Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease", IJMS journal, MDPI, is to present the impact in clinical practice as well as in medical research of novel molecules that have been introduced in the treatment of diabetes mellitus, dyslipidemia, and cardiovascular disease. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Research & information: general |2 bicssc | |
| 650 | 7 | |a Biology, life sciences |2 bicssc | |
| 653 | |a nicotinamide mononucleotide | ||
| 653 | |a retinal ischemia/reperfusion | ||
| 653 | |a oxidative stress | ||
| 653 | |a neuroprotection | ||
| 653 | |a inflammation | ||
| 653 | |a sacubitril/valsartan | ||
| 653 | |a mortality | ||
| 653 | |a morbidity | ||
| 653 | |a heart failure | ||
| 653 | |a ejection fraction | ||
| 653 | |a diabetes mellitus | ||
| 653 | |a α-glucosidase | ||
| 653 | |a abietane diterpenoids | ||
| 653 | |a levopimaric acid | ||
| 653 | |a quinopimaric acid | ||
| 653 | |a molecular docking | ||
| 653 | |a ADMET | ||
| 653 | |a PFK15 synthesis | ||
| 653 | |a sunitinib L-malate | ||
| 653 | |a HUVEC | ||
| 653 | |a angiogenesis | ||
| 653 | |a synergy | ||
| 653 | |a cardiovascular medicine | ||
| 653 | |a diabetes | ||
| 653 | |a hypertension | ||
| 653 | |a GIP | ||
| 653 | |a GLP-1 | ||
| 653 | |a glucagon | ||
| 653 | |a incretins | ||
| 653 | |a LY3298176 | ||
| 653 | |a meta-analysis | ||
| 653 | |a obesity | ||
| 653 | |a SUMMIT | ||
| 653 | |a SURMOUNT | ||
| 653 | |a SURPASS | ||
| 653 | |a SYNERGY | ||
| 653 | |a Tirzepatide | ||
| 653 | |a common carotid artery occlusion | ||
| 653 | |a retinal ischemia | ||
| 653 | |a dyslipidemia | ||
| 653 | |a statin | ||
| 653 | |a children | ||
| 653 | |a adolescents | ||
| 653 | |a metabolic syndrome | ||
| 653 | |a liver | ||
| 653 | |a hsa-miR-193b-3p | ||
| 653 | |a peroxisome proliferator activated receptor gamma coactivator 1 alpha | ||
| 653 | |a lipid metabolism | ||
| 653 | |a n/a | ||
| 653 | |a empagliflozin | ||
| 653 | |a type 2 diabetes mellitus | ||
| 653 | |a leptin | ||
| 653 | |a sphingolipids | ||
| 653 | |a sphingomyelinase | ||
| 653 | |a vasorelaxation | ||
| 653 | |a endothelial nitric oxide synthase | ||
| 653 | |a type 2 diabetes | ||
| 653 | |a thromboxane prostanoid receptor | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/7293 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/100830 |7 0 |z DOAB: description of the publication |